PATENT CLAIM ANALYSIS

Application Number: 15865339
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "019000"]

Abstract:
A phosphodiesterase type III (PDE III) inhibitor or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Claim (Index 17):
The method of  claim 1 , wherein pimobendan or a pharmaceutically acceptable salt thereof is administered together with one or more medicaments selected from the group consisting of one or more ACE inhibitors, one or more diuretics and one or more digitalis glycosides.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.30303
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14175175', '11087465', '12482481', '13832292', '14401943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8006056244111853
- 35 USC 102 Novelty (BERT): 0.5850546125898954
- Combined Prediction Score: 0.7790505232290564
- Mean Citation Score: 413.59645200000006
- Max Citation Score: 481.5739
- Similarity Product: 431.7638059357584

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test